Stay updated on Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial
Sign up to get notified when there's something new on the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page.

Latest updates to the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page
- Check7 days agoChange DetectedAdded a Locations section listing Maryland as a study site. Removed the HHS Vulnerability Disclosure link and the older Maryland Locations entry.SummaryDifference0.2%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check36 days agoChange DetectedRevision label updated from v3.2.0 to v3.3.2. This change does not modify the study details or eligibility criteria.SummaryDifference0.1%

- Check43 days agoChange DetectedRemoval of the government funding/status notice; core study information including interventions, eligibility criteria, and outcomes remains unchanged. The administrative notice removed does not affect the study details or enrollment processes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check57 days agoChange DetectedThe changes are limited to minor formatting and wording updates on the Study Details page and do not affect core content such as eligibility criteria, outcomes, or enrollment. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check86 days agoChange Detected- Updated operating-status notice and new version tag (v3.2.0) added; old version tag (v3.1.0) removed. The page now provides current status guidance and a newer software/document version.SummaryDifference3%

- Check93 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0.SummaryDifference0.1%

Stay in the know with updates to Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page.